We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

By LabMedica International staff writers
Posted on 13 Apr 2015
Print article
The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology and to extend targeted therapeutics programs.

With the incorporation of this proteomic capability, nCounter Analysis System will hold a unique distinction of having capabilities for concurrent genomic and proteomic analysis. "These types of assays are designed to provide a powerful tool for comprehensively probing tumor biology, with potential to capture the biology needed to optimize the use of new cancer therapeutics, especially in the dynamic field of immuno-oncology, where matching patients with the right combination of therapies is critical," said Gordon Mills, MD, PhD, chair of Systems Biology at MD Anderson, and co-director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Dr. Mills will lead the collaboration effort.

NanoString’s beta launch of the first panel for simultaneous measurement of gene and protein expression on April 18–22, 2015, at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia (PA, USA) included a talk by Joe Beechem, PhD, titled "Simultaneous multi-omic measurement of gene fusions, mRNA, and proteins at 800-plex using single-molecule optical barcodes."

nCounter Analysis System is an automated, easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high-precision multiplexed assays across various research applications. nCounter technology uses color-coded molecular barcodes that can hybridize directly to many different types of target molecules. Assays are enzyme-free and capable of generating high-quality results from challenging sample types, including FFPE tissue.

"In collaboration with experts at MD Anderson, we will be adding a new proteomic dimension to [our] assays, aiming to demonstrate their potential to inform drug development and selection,” said Brad Gray, president and CEO, NanoString Technologies.

Under the terms of the agreement, NanoString is granted rights to research and diagnostic content developed within the scope of the collaboration. Key partnership objectives include: development of multi-omic assays and signatures that profile key oncology disease pathways and immune response from tumor tissue; incorporation of these multi-omic assays into select clinical studies at MD Anderson to predict and monitor response to therapies (both as single agents and combinations); and identification of clinically actionable proteomic markers across multiple tumor types.

Related Links:

NanoString Technologies
University of Texas MD Anderson Cancer Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.